News

With respect to the ongoing development of atacicept, an investigational drug for the treatment of various autoimmune diseases and B-cell malignancies, ZymoGenetics has exercised its contractual right to

Under the terms of the agreement, Medivation will receive an up-front cash payment of $225 million. Medivation also is eligible to receive payments of up to $500 million

As part of this collaboration, Opexa and the Myelin Repair Foundation (MRF) will work to identify therapeutically relevant biomarkers in multiple sclerosis (MS) that may provide important insight

The AZ-004 clinical trial enrolled 344 schizophrenic patients with acute agitation at 24 US clinical centers. The trial was designed as an in-clinic, multi-center, randomized, double-blind, placebo-controlled study

Threshold sold 8.97 million shares of its common stock at $2.04 per share, and warrants to purchase up to 3.58 million shares of its common stock for gross

According to the company, the grant was provided to support development of additional formulations and smallpox-related indications for ST-246, Siga’s lead drug candidate. ST-246 is said to be

Neurotech is conducting two Phase II/III trials of NT-501 for the treatment of visual loss associated with retinitis pigmentosa (RP)-one consisting of patients with earlier stage disease (60

Corcept has previously published the results of studies in rats that demonstrated that CORLUX, a potent GRII (cortisol) receptor antagonist, both reduced the weight gain associated with the

Dr Connor joins Halozyme from Ardea Biosciences where he was senior vice president and chief scientific officer. His responsibilities will include leadership of Halozyme’s multiple biology and chemistry